Bioanalysis
Strategies to Improve Assay Sensitivity for Bioanalysis of Therapeutic Oligonucleotides Through Ligand Binding Assays
Accelerated Study Timelines, Less Logistical Hurdles
The True Meaning of Moving in Unison
We value your time as much as you do. At Altasciences, we break down organizational silos, streamline project management, and promote effortless communication to provide you with exceptional value.
From preclinical studies to clinical trials, and from regulatory submissions to tackling operational challenges, we are dedicated to safely accelerating your journey from lead candidate selection to proof of concept and beyond using a seamless and integrated approach to drug development.
Let's get your project started! Speak with an expert today.
The Altascientist Issue 41: Immunomodulation Assessments for Clinical Trials–Sophisticated Bioanalytical Approaches to Support Complex Modalities
Optimize Your Gene Therapy Strategies With This eBook (3 Case Studies Included)
A Comprehensive Guide to Gene Therapy and Improving AAV Efficiency
Entrust your gene therapy research to an experienced CRO like Altasciences.
Our work with CRISPR gene-editing therapeutics in nonhuman primates (NHPs) encompasses a variety of administration routes, supported by our extensive bioanalytical capabilities to conduct biodistribution studies.
Find out more about:
- how to navigate the regulatory landscape;
- how to optimize the safety and efficacy of AAV-based therapies;
- Altasciences’ track record in gene therapy studies; and
- how Altasciences can support your gene therapy studies.
Three supporting case studies are included!
You may also be interested in the below:
-
The Altascientist:
- Nonclinical Studies in Cell and Gene Therapy
- Quantitative PCR (qPCR) and droplet digital (ddPCR) for Your Gene Therapy Programs
-
Webpages:
- Bioanalytical Services
- Preclinical Services
Key Considerations for Nonclinical AAV Gene Therapy Development
How We Used Singlicate Analysis to Optimize Resource Utilization
Achieving Efficiency and Cost Savings in Drug Development
In the fast-paced world of drug development, where every sample counts, finding ways to optimize resources and accelerate results is critical.
In this poster presentation, we discuss singlicate analysis, an innovative approach that focuses on individual samples to streamline processes. This method is ideal for managing the data-intensive demands of drug discovery, whether in the GLP or non-GLP phases. It's particularly effective across various matrices, drug entities, and biomarkers.
Watch to find out how we slashed consumable costs, maximized resource utilization, and accelerated data generation.
If you want to enhance efficiency without compromising on data quality, singlicate analysis could be the game-changer your studies need.
Speak with an expert to learn more about how this approach can be tailored to your specific needs.
You may also be interested in the below poster presentations:
- Sensitive Quantitation of ASOs Using Microsampling Coupled with Hybridization LC-MS/MS
- Development of an Assay for Atropine in Rabbit Plasma by LC-MS/MS and the Impact of Atropine Esterase
- Strategies to Improve Assay Sensitivity to Quantify Therapeutic Oligonucleotides
Metabolic Drug Development: A to Z Solutions
In the complex and dynamic field of metabolic drug development, partnering with an accomplished contract research organization is essential.
Altasciences has over 25 years of experience in metabolic diseases and supports every stage of the development process, from the initial discovery phase and preclinical studies to clinical trials and beyond.
Here are a few highlights:
- The teams at our four preclinical sites are proficient in obesity and metabolic models, and both GLP and non-GLP studies in rodents, dogs, minipigs, and NHPs.
- Our clinical teams have completed over 50 early-stage trials involving anti-diabetic and hypoglycemic agents, such as insulin, GLP-1, SGLT-2, and DPP-4, with 75 type I and type II diabetic patients enrolled in a single-center trial over four weeks.
- Our clinical database includes over 400,000 participants to more quickly qualify for inclusion/exclusion criteria based on pre-existing conditions, demographics, medication use, and BMI.
- Our scientists have developed bioanalytical assays for exenatide, glucagon, insulin glargine (M1, M2), insulin aspart, and metformin.
- We can develop additional assays tailored to your program.
- We’ve conducted numerous pharmacodynamics and immunogenicity assessments, including high-glycemic load challenge/tolerance tests, glucose clamps, insulin-induced hypoglycemic events in type 1 diabetes, and anti-drug antibody evaluations.
- We support data management both at our clinics and at external sites.
- Our pharmacokinetic, pharmacodynamic, and statistical experts support the analysis of drug concentration, biomarker, subjective measure, and immunogenicity data.
- Our medical writers and scientists have designed thousands of studies and are accustomed to preparing clinical protocols and high-quality reports.
Ready to get started? Speak with one of our experts.
You may also be interested in the following resources:
- Webpage: Metabolism and Endocrinology
- The Altascientist: The Many Faces of Metabolic Disorders
- Case Study: Concomitant Administration of Multiple Doses of Cagrilintide With Semaglutide 2·4 mg for Weight Management
Three Labs, One Vision—Harmonizing Excellence and Experience
Reliable Data for Your Unique Needs
We understand that your research needs are unique, and that's why you can trust us to provide data that aligns with your specific requirements.
Part 1 of our video series reveals how our three laboratories, strategically located across North America and unified by mirrored processes, ensure consistent, reliable results.
This underlines our dedication to scientific excellence and seamless synergies.
You may also be interested in the following:
- Altasciences Resource Center (scientific publications, eBooks, webinars, and more!)
- Bioanalytical Services
- Preclinical Services
- Clinical Services
My Attendance at the 2024 Boston Society Cell and Gene Therapy Conference
My fellow Altascientists and I recently attended the 2024 annual Boston Society Gen